Selected article for: "ALI inflammatory response and inflammatory response"
Author: Corominas, Hèctor; Castellví, Ivan; Pomar, Virginia; Antonijoan, Rosa; Mur, Isabel; Matas, Laia; Gich, Ignasi; de Benito, Natividad; Laiz, Ana; Castillo, Diego; Villamarin, Laura; Filella, David; Millán, Ana Milena; Quijada, María Ángeles; Puig, Mireia; Casademont, Jordi; Domingo, Pere
Title: Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort()
  • Cord-id: 4buq4k4l
  • Document date: 2020_11_12
    • ID: 4buq4k4l
    Snippet: Although the starting event in COVID-19 is a viral infection some patients present with an over-exuberant inflammatory response, leading to acute lung injury (ALI) and adult respiratory distress syndrome (ARDS). Since IL-6 plays a critical role in the inflammatory response, we assessed the efficacy and safety of tocilizumab (TCZ) in this single-centre, observational study in all Covid-19 in-patient with a proven SARS-CoV-2 rapidly progressing infection to prevent ALI and ARDS. 104 patients with
    Document: Although the starting event in COVID-19 is a viral infection some patients present with an over-exuberant inflammatory response, leading to acute lung injury (ALI) and adult respiratory distress syndrome (ARDS). Since IL-6 plays a critical role in the inflammatory response, we assessed the efficacy and safety of tocilizumab (TCZ) in this single-centre, observational study in all Covid-19 in-patient with a proven SARS-CoV-2 rapidly progressing infection to prevent ALI and ARDS. 104 patients with COVID-19 treated with TCZ had a lower mortality rate (5·8%) compared with the regional mortality rate (11%), hospitalized patient's mortality (10%), and slightly lower than hospitalized patients treated with our standard of care alone (6%). We found that TCZ rapidly decreased acute phase reactants, ferritin and liver release of proteins. D-Dimer decreased slowly. We did not observe specific safety concerns. Early administration of IL6-R antagonists in COVID-19 patients with impending hyperinflammatory response, may be safe and effective treatment to prevent, ICU admission and further complications.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and liver function: 1, 2, 3, 4, 5, 6, 7, 8
    • acute ards respiratory distress syndrome and liver function test: 1, 2
    • acute ards respiratory distress syndrome and liver protein: 1
    • acute ards respiratory distress syndrome and lung function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lupus erythematosus: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome lead and lung function: 1
    • acute ards respiratory distress syndrome lead and lupus erythematosus: 1
    • acute phase and liver function: 1, 2, 3, 4, 5, 6, 7
    • acute phase and liver protein: 1, 2, 3, 4, 5, 6, 7, 8
    • acute phase and lung function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • acute phase and lupus erythematosus: 1, 2
    • acute phase and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute phase and lymphocyte count decrease: 1, 2
    • acute respiratory syndrome and lung function test: 1, 2
    • acute respiratory syndrome and lung functional disability: 1, 2
    • acute respiratory syndrome and lupus erythematosus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lymphocyte count decrease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10